Filtered By:
Condition: Guillain-Barr Syndrome
Vaccination: Vaccines

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 141 results found since Jan 2013.

Central Nervous System Complications of Varicella-Zoster Virus
Conclusion: Neurologic complications of VZV infection continue to occur despite the availability of an effective vaccine. Neurologic symptom onset can predate the appearance of the VZV exanthem and in rare cases may occur in the absence of an exanthem.
Source: The Journal of Pediatrics - July 24, 2014 Category: Pediatrics Authors: Michelle Science, Daune MacGregor, Susan E. Richardson, Sanjay Mahant, Dat Tran, Ari Bitnun Tags: Original Articles Source Type: research

One-Third of COVID-19 Survivors May Develop a Neuropsychiatric Disorder Within Months of Infection
One-third of individuals diagnosed with COVID-19 developed a psychiatric or neurological problem within six months of their diagnosis, according to astudy published Tuesday inThe Lancet Psychiatry. The prevalence of a post-COVID neurologic or psychiatric diagnosis was even greater among individuals with severe illness who had required hospitalization.“Given the size of the pandemic and the chronicity of many of the diagnoses and their consequences (for example, dementia, stroke, and intracranial hemorrhage), substantial effects on health and social care systems are likely to occur,” wrote Maxime Taque, Ph.D., of the Un...
Source: Psychiatr News - April 7, 2021 Category: Psychiatry Tags: anxiety COVID-19 electronic health records hospitalizations mood disorders neuropsychiatric disorders The Lancet Psychiatry Source Type: research

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic
CONCLUSION: Rates of some clinical outcomes during the pandemic changed and should not be used as historical background rates in vaccine safety studies. Inclusion of telehealth visits should be considered for vaccine studies involving Bell's palsy, ITP, and narcolepsy/cataplexy.PMID:35465977 | DOI:10.1016/j.vaccine.2022.04.037
Source: Vaccine - April 25, 2022 Category: Allergy & Immunology Authors: Stanley Xu Vennis Hong Lina S Sy Sungching C Glenn Denison S Ryan Kerresa L Morrissette Jennifer C Nelson Simon J Hambidge Bradley Crane Ousseny Zerbo Malini B DeSilva Jason M Glanz James G Donahue Elizabeth Liles Jonathan Duffy Lei Qian Source Type: research

Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
Ther Adv Drug Saf. 2023 May 21;14:20420986231165674. doi: 10.1177/20420986231165674. eCollection 2023.ABSTRACTAmid the coronavirus disease 2019 (COVID-19) pandemic, massive immunization campaigns became the most promising public health measure. During clinical trials, certain neurological adverse effects following immunization (AEFIs) were observed; however, acceptable safety profiles lead to emergency authorization for the distribution and use of the vaccines. To contribute to pharmacovigilance and lessen the potential negative impact that vaccine hesitancy would have on immunization programs, we conducted a review of the...
Source: Adv Data - May 24, 2023 Category: Epidemiology Authors: Sara Eslait-Olaciregui Kevin Llin ás-Caballero David Pati ño-Manjarrés Thomas Urbina-Ariza Juan Fernando Cediel-Becerra Camilo Alberto Dom ínguez-Domínguez Source Type: research

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
CONCLUSIONS: In this safety surveillance study of more than 200,000 DTaP-IPV vaccine recipients, there was no evidence of increased risk for any of the pre-specified adverse events monitored. Continued surveillance of DTaP-IPV vaccine safety may be warranted to monitor for rare adverse events, such as Guillain-Barré syndrome. PMID: 24699471 [PubMed - as supplied by publisher]
Source: Vaccine - March 31, 2014 Category: Allergy & Immunology Authors: Daley MF, Yih WK, Glanz JM, Hambidge SJ, Narwaney KJ, Yin R, Li L, Nelson JC, Nordin JD, Klein NP, Jacobsen SJ, Weintraub E Tags: Vaccine Source Type: research

COVID-19 Infection and Neurological Complications: Present Findings and Future Predictions
The present outbreak caused by SARS-CoV-2, an influenza virus with neurotropic potential, presents with neurological manifestations in a large proportion of the affected individuals. Disorders of the central and peripheral nervous system are all present, while stroke, ataxia, seizures, and depressed level of consciousness are more common in severely affected patients. People with these severe complications are most likely elderly with medical comorbidities, especially hypertension and other vascular risk factors. However, postinfectious complications are also expected. Neurological disorders as sequelae of influenza viruse...
Source: Neuroepidemiology - July 1, 2020 Category: Epidemiology Source Type: research

Complete Oculomotor Palsy after Influenza Vaccination in a Young Healthy Adult: A Case Report
We present a case report of a 25-year-old woman without any medical history who developed complete oculomotor palsy 2 weeks after influenza vaccination. Other possible causes of oculomotor nerve palsy, such as stroke, compressive lesions, infections, and autoimmune disorders, were eliminated by blood tests, cerebrospinal fluid examination, and imaging studies. Hence, influenza vaccine was considered as the likely cause.Case Rep Neurol 2021;13:35 –39
Source: Case Reports in Neurology - January 25, 2021 Category: Neurology Source Type: research

Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature
ConclusionTo our knowledge, this is the one of early reported case of transverse myelitis and with post SARS-CoV-2 vaccination, who responded well to plasmapheresis. Further studies would be recommended to identify the underlying correlation between COVID-19 vaccination and transverse myelitis.
Source: Journal of Neurology - September 5, 2021 Category: Neurology Source Type: research

Neuro ‐COVID‐19
AbstractNeuromuscular manifestations of new coronavirus infection (COVID-19) are frequent and include dizziness, headache, myopathy, and olfactory and gustatory disturbances. Patients with acute central nervous system (CNS) disorders, such as delirium, impaired consciousness, stroke, and convulsive seizures, have a high mortality rate. The encephalitis/encephalopathy that causes consciousness disturbance and seizures can be classified into three conditions, including direct infection with the SARS-CoV-2 virus, encephalopathy caused by CNS damage secondary to systemic hypercytokinemia (cytokine storm), and autoimmune-mediat...
Source: Clinical and Experimental Neuroimmunology - September 12, 2021 Category: Neurology Authors: Takayoshi Shimohata Tags: REVIEW ARTICLE Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early-Onset Myasthenia Gravis Following COVID-19 Vaccination
J Korean Med Sci. 2022 Mar 14;37(10):e50. doi: 10.3346/jkms.2022.37.e50.ABSTRACTAs coronavirus disease 2019 (COVID-19) has spread worldwide, the rate of COVID-19 vaccination uptake is encouraging. Neurological complications associated with COVID-19 vaccines such as stroke, Guillain-Barré syndrome, and Bell's palsy have been reported. Recently, late-onset myasthenia gravis (MG) following COVID-19 vaccination has been reported. To date, however, there has been no evidence of increased risk of early-onset MG following COVID-19. Here, we report a case of a patient with new-onset MG that arose after receiving a COVID-19 vaccin...
Source: J Korean Med Sci - March 15, 2022 Category: General Medicine Authors: Myung Ah Lee Chonghwee Lee Jung Hyun Park Jung Hwan Lee Source Type: research